Literature DB >> 9177742

Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

C L Crespi1, V P Miller, B W Penman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9177742     DOI： 10.1006/abio.1997.2145

Source DB:  PubMed          Journal:  Anal Biochem        ISSN： 0003-2697            Impact factor:   3.365


× No keyword cloud information.
  48 in total

1.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme.

Authors:  N Miyata; K Taniguchi; T Seki; T Ishimoto; M Sato-Watanabe; Y Yasuda; M Doi; S Kametani; Y Tomishima; T Ueki; M Sato; K Kameo
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

3.  Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses.

Authors:  Z Yan; B Rafferty; G W Caldwell; J A Masucci
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

4.  Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.

Authors:  Edith J Mensah-Osman; Dafydd G Thomas; Michelle M Tabb; Jose M Larios; Dennis P Hughes; Thomas J Giordano; Michelle L Lizyness; James M Rae; Bruce Blumberg; Paul F Hollenberg; Laurence H Baker
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

5.  High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.

Authors:  B Oxombre; C Lee-Chang; A Duhamel; M Toussaint; M Giroux; M Donnier-Maréchal; P Carato; D Lefranc; H Zéphir; L Prin; P Melnyk; P Vermersch
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

6.  Cytochrome P450 2C24: Expression, Tissue Distribution, High-Throughput Assay, and Pharmacological Inhibition.

Authors:  Jun Yang; Melissa A VanAlstine; James G Phillips; Mark P Wentland; Lindsay B Hough
Journal:  Acta Pharm Sin B       Date:  2012-04       Impact factor: 11.413

7.  Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.

Authors:  Cheng Li; Dong-Hyun Choi; Jun-Shik Choi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-01       Impact factor: 2.745

8.  Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds.

Authors:  Jair L Siqueira-Neto; Ok-Ryul Song; Hyunrim Oh; Jeong-Hun Sohn; Gyongseon Yang; Jiyoun Nam; Jiyeon Jang; Jonathan Cechetto; Chang Bok Lee; Seunghyun Moon; Auguste Genovesio; Eric Chatelain; Thierry Christophe; Lucio H Freitas-Junior
Journal:  PLoS Negl Trop Dis       Date:  2010-05-04

9.  Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.

Authors:  Robert H Barker; Hanlan Liu; Bradford Hirth; Cassandra A Celatka; Richard Fitzpatrick; Yibin Xiang; Erin K Willert; Margaret A Phillips; Marcel Kaiser; Cyrus J Bacchi; Aixa Rodriguez; Nigel Yarlett; Jeffrey D Klinger; Edmund Sybertz
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

10.  High-throughput fluorescence assay of cytochrome P450 3A4.

Authors:  Qian Cheng; F Peter Guengerich
Journal:  Methods Mol Biol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.